These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 33140566)

  • 1. Sitagliptin for the prevention and treatment of perioperative hyperglycaemia in patients with type 2 diabetes undergoing cardiac surgery: A randomized controlled trial.
    Cardona S; Tsegka K; Pasquel FJ; Jacobs S; Halkos M; Keeling WB; Davis GM; Fayfman M; Albury B; Urrutia MA; Galindo RJ; Migdal AL; Macheers S; Guyton RA; Vellanki P; Peng L; Umpierrez GE
    Diabetes Obes Metab; 2021 Feb; 23(2):480-488. PubMed ID: 33140566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sitagliptin for the prevention of stress hyperglycemia in patients without diabetes undergoing coronary artery bypass graft (CABG) surgery.
    Cardona S; Tsegka K; Pasquel FJ; Fayfman M; Peng L; Jacobs S; Vellanki P; Halkos M; Guyton RA; Thourani VH; Galindo RJ; Umpierrez G
    BMJ Open Diabetes Res Care; 2019; 7(1):e000703. PubMed ID: 31543976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of sitagliptin for the hospital management of general medicine and surgery patients with type 2 diabetes (Sita-Hospital): a multicentre, prospective, open-label, non-inferiority randomised trial.
    Pasquel FJ; Gianchandani R; Rubin DJ; Dungan KM; Anzola I; Gomez PC; Peng L; Hodish I; Bodnar T; Wesorick D; Balakrishnan V; Osei K; Umpierrez GE
    Lancet Diabetes Endocrinol; 2017 Feb; 5(2):125-133. PubMed ID: 27964837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sitagliptin for prevention of stress hyperglycemia in patients without diabetes undergoing general surgery: A pilot randomized study.
    Fayfman M; Davis G; Duggan EW; Urrutia M; Chachkhiani D; Schindler J; Pasquel FJ; Galindo RJ; Vellanki P; Reyes-Umpierrez D; Wang H; Umpierrez GE
    J Diabetes Complications; 2018 Dec; 32(12):1091-1096. PubMed ID: 30253968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intensive intraoperative insulin therapy versus conventional glucose management during cardiac surgery: a randomized trial.
    Gandhi GY; Nuttall GA; Abel MD; Mullany CJ; Schaff HV; O'Brien PC; Johnson MG; Williams AR; Cutshall SM; Mundy LM; Rizza RA; McMahon MM
    Ann Intern Med; 2007 Feb; 146(4):233-43. PubMed ID: 17310047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of sitagliptin therapy for the inpatient management of general medicine and surgery patients with type 2 diabetes: a pilot, randomized, controlled study.
    Umpierrez GE; Gianchandani R; Smiley D; Jacobs S; Wesorick DH; Newton C; Farrokhi F; Peng L; Reyes D; Lathkar-Pradhan S; Pasquel F
    Diabetes Care; 2013 Nov; 36(11):3430-5. PubMed ID: 23877988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects on the glucagon response to hypoglycaemia during DPP-4 inhibition in elderly subjects with type 2 diabetes: A randomized, placebo-controlled study.
    Farngren J; Persson M; Ahrén B
    Diabetes Obes Metab; 2018 Aug; 20(8):1911-1920. PubMed ID: 29645341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial.
    Ahrén B; Masmiquel L; Kumar H; Sargin M; Karsbøl JD; Jacobsen SH; Chow F
    Lancet Diabetes Endocrinol; 2017 May; 5(5):341-354. PubMed ID: 28385659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liraglutide for perioperative management of hyperglycaemia in cardiac surgery patients: a multicentre randomized superiority trial.
    Hulst AH; Visscher MJ; Godfried MB; Thiel B; Gerritse BM; Scohy TV; Bouwman RA; Willemsen MGA; Hollmann MW; Preckel B; DeVries JH; Hermanides J;
    Diabetes Obes Metab; 2020 Apr; 22(4):557-565. PubMed ID: 31749275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of Sitagliptin With Closed-Loop Technology to Decrease Postprandial Blood Glucose in Type 1 Diabetes.
    Underland LJ; Ilkowitz JT; Katikaneni R; Dowd A; Heptulla RA
    J Diabetes Sci Technol; 2017 May; 11(3):602-610. PubMed ID: 28349708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hospitalization costs and clinical outcomes in CABG patients treated with intensive insulin therapy.
    Cardona S; Pasquel FJ; Fayfman M; Peng L; Jacobs S; Vellanki P; Weaver J; Halkos M; Guyton RA; Thourani VH; Umpierrez GE
    J Diabetes Complications; 2017 Apr; 31(4):742-747. PubMed ID: 28161384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combining the G-protein-coupled receptor 40 agonist fasiglifam with sitagliptin improves glycaemic control in patients with type 2 diabetes with or without metformin: A randomized, 12-week trial.
    Peng XV; Marcinak JF; Raanan MG; Cao C
    Diabetes Obes Metab; 2017 Aug; 19(8):1127-1134. PubMed ID: 28239939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial.
    Pieber TR; Bode B; Mertens A; Cho YM; Christiansen E; Hertz CL; Wallenstein SOR; Buse JB;
    Lancet Diabetes Endocrinol; 2019 Jul; 7(7):528-539. PubMed ID: 31189520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes.
    Brazg R; Xu L; Dalla Man C; Cobelli C; Thomas K; Stein PP
    Diabetes Obes Metab; 2007 Mar; 9(2):186-93. PubMed ID: 17300594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of tight intraoperative glycemic control during off-pump coronary artery bypass surgery in diabetic and nondiabetic patients.
    Lecomte P; Foubert L; Coddens J; Dewulf B; Nobels F; Casselman F; Cammu G
    J Cardiothorac Vasc Anesth; 2011 Dec; 25(6):937-42. PubMed ID: 21640613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metformin as an adjunct to insulin for glycemic control in patients with type 2 diabetes after CABG surgery: a randomized double blind clinical trial.
    Baradari AG; Emami Zeydi A; Aarabi M; Ghafari R
    Pak J Biol Sci; 2011 Dec; 14(23):1047-54. PubMed ID: 22590838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
    Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
    Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
    Rosenstock J; Brazg R; Andryuk PJ; Lu K; Stein P;
    Clin Ther; 2006 Oct; 28(10):1556-68. PubMed ID: 17157112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of sitagliptin on post-prandial glucagon and GLP-1 levels in patients with type 1 diabetes: investigator-initiated, double-blind, randomized, placebo-controlled trial.
    Garg SK; Moser EG; Bode BW; Klaff LJ; Hiatt WR; Beatson C; Snell-Bergeon JK
    Endocr Pract; 2013; 19(1):19-28. PubMed ID: 23186950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus.
    Aaboe K; Knop FK; Vilsbøll T; Deacon CF; Holst JJ; Madsbad S; Krarup T
    Diabetes Obes Metab; 2010 Apr; 12(4):323-33. PubMed ID: 20380653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.